Akari Therapeutics (AKTX) Other Operating Expenses (2015 - 2026)

Akari Therapeutics has disclosed Other Operating Expenses across 3 years of filings, most recently posting $12.1 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $12.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (up 177.18% YoY), and the FY2025 annual result was $5.2 million, up 126.17% from the prior year.
• Other Operating Expenses came in at $12.1 million for Q1 2026 at Akari Therapeutics, up from -$3.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $12.1 million in Q1 2026 to a low of -$7.6 million in Q1 2024.